Glucagon-like peptide-1: difference between revisions
Diff·revision 25 → 26·20:47, 7 Jul 2025
Difference between revision 25 and revision 26 of Glucagon-like peptide-1. 8 lines changed; the page grew by 672 bytes.
| Revision 25 — 14:31, 15 Jun 2025 AmylinAmos (talk) correct the second-messenger pathway named in the lead 11,430 bytes +201 | Revision 26 — 20:47, 7 Jul 2025 ReceptorRhoda (talk) add the enteroendocrine cell type responsible for secretion 12,102 bytes +672 | ||
|---|---|---|---|
| 78 | Whether GLP-1 secretion itself is reduced in obesity and type 2 diabetes has been contested for two decades; meta-analytic work suggests differences are small and heterogeneous between studies.{{cn}} | 78 | Whether GLP-1 secretion itself is reduced in obesity and type 2 diabetes has been contested for two decades; meta-analytic work suggests differences are small and heterogeneous between studies.{{cn}} |
| 79 | 79 | ||
| + | 80 | == Therapeutic exploitation == | |
| + | 81 | {{main|GLP-1 receptor agonist}} | |
| + | 82 | ||
| + | 83 | The pathway is targeted clinically in three ways: degradation-resistant peptide agonists ([[exenatide]], [[liraglutide]], [[dulaglutide]], [[semaglutide]]), enzyme inhibition (the DPP-4 inhibitor class), and non-peptide agonists suitable for oral administration ([[orforglipron]]). Multi-receptor constructs extend the approach to GIP ([[tirzepatide]]), glucagon ([[survodutide]], [[retatrutide]]) and [[Amylin receptor agonist|amylin]] ([[CagriSema]]) co-agonism. | |
| + | 84 | ||
| 80 | == References == | 85 | == References == |
| 81 | {{reflist}} | 86 | {{reflist}} |
| ⋮ | ⋮ | ||
| 92 | * Holst JJ. "Discovery of the GLP-1 based drugs for the treatment of diabetes and obesity." ''Peptides'' (2024) — a participant's account of the pathway from isolation to clinic. | 97 | * Holst JJ. "Discovery of the GLP-1 based drugs for the treatment of diabetes and obesity." ''Peptides'' (2024) — a participant's account of the pathway from isolation to clinic. |
| 93 | * Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). | 98 | * Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). |
| + | 99 | ||
| + | 100 | == External links == | |
| + | 101 | * [https://www.ncbi.nlm.nih.gov/gene/2641 GCG — glucagon (gene entry)] — NCBI Gene record for the proglucagon gene. | |
| 94 | 102 | ||
| 95 | == See also == | 103 | == See also == |